- Home
- ACRV vs TVGN Comparison
ACRV vs TVGN Comparison
Compare ACRV & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRV | TVGN |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 89.3M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRV | TVGN |
|---|---|---|
| Price | $2.39 | $0.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $14.67 | $5.00 |
| AVG Volume (30 Days) | ★ 1.3M | 611.4K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $805.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $0.38 |
| 52 Week High | $8.00 | $1.92 |
Technical Indicators
Market Signals| Indicator | ACRV | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.76 | 37.34 |
| Support Level | $2.22 | $0.41 |
| Resistance Level | $2.39 | $0.50 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 86.15 | 27.29 |
Price Performance
Historical ComparisonAbout ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.